JP2024540275A5 - - Google Patents

Info

Publication number
JP2024540275A5
JP2024540275A5 JP2024526511A JP2024526511A JP2024540275A5 JP 2024540275 A5 JP2024540275 A5 JP 2024540275A5 JP 2024526511 A JP2024526511 A JP 2024526511A JP 2024526511 A JP2024526511 A JP 2024526511A JP 2024540275 A5 JP2024540275 A5 JP 2024540275A5
Authority
JP
Japan
Prior art keywords
approximately
car
cells
response
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540275A (ja
Filing date
Publication date
Priority claimed from PCT/CN2021/128578 external-priority patent/WO2023077343A1/en
Application filed filed Critical
Priority claimed from PCT/US2022/079216 external-priority patent/WO2023081752A1/en
Publication of JP2024540275A publication Critical patent/JP2024540275A/ja
Publication of JP2024540275A5 publication Critical patent/JP2024540275A5/ja
Pending legal-status Critical Current

Links

JP2024526511A 2021-11-04 2022-11-03 Bcmaを標的とする、多発性骨髄腫のためのcar-t細胞療法関連出願の相互参照 Pending JP2024540275A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275471P 2021-11-04 2021-11-04
CNPCT/CN2021/128578 2021-11-04
PCT/CN2021/128578 WO2023077343A1 (en) 2021-11-04 2021-11-04 Bcma-targeted car-t cell therapy for multiple myeloma
US63/275,471 2021-11-04
PCT/US2022/079216 WO2023081752A1 (en) 2021-11-04 2022-11-03 Bcma-targeted car-t cell therapy for multiple myeloma

Publications (2)

Publication Number Publication Date
JP2024540275A JP2024540275A (ja) 2024-10-31
JP2024540275A5 true JP2024540275A5 (cg-RX-API-DMAC7.html) 2025-11-11

Family

ID=84370104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526511A Pending JP2024540275A (ja) 2021-11-04 2022-11-03 Bcmaを標的とする、多発性骨髄腫のためのcar-t細胞療法関連出願の相互参照

Country Status (11)

Country Link
US (1) US20230277589A1 (cg-RX-API-DMAC7.html)
EP (1) EP4426737A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540275A (cg-RX-API-DMAC7.html)
KR (1) KR20240117530A (cg-RX-API-DMAC7.html)
CN (1) CN118510801A (cg-RX-API-DMAC7.html)
AU (1) AU2022381186A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237341A1 (cg-RX-API-DMAC7.html)
IL (1) IL312602A (cg-RX-API-DMAC7.html)
JO (1) JOP20240104A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005461A (cg-RX-API-DMAC7.html)
WO (1) WO2023081752A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12522645B2 (en) 2019-11-05 2026-01-13 Janssen Biotech, Inc. BCMA-targeted CAR-T cell therapy of multiple myeloma
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
KR20260085124A (ko) * 2023-10-05 2026-06-08 얀센 바이오테크 인코포레이티드 Car-t 세포 의약품의 생성을 위한 렌티바이러스 제조의 개선된 방법
US20250144234A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics Inc. RNA for In vivo Transfection with Increased Expression
AU2025218081A1 (en) * 2024-02-05 2026-07-16 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディとその使用
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
TW202020146A (zh) * 2018-07-26 2020-06-01 大陸商南京傳奇生物科技有限公司 含nef之t細胞及其產生方法

Similar Documents

Publication Publication Date Title
US20250262318A1 (en) Methods and pharmaceutical composition for the treatment of cancer
CN112384534A (zh) 用于增强nk细胞对靶细胞的杀死的组合物和方法
JP2022513420A5 (cg-RX-API-DMAC7.html)
JP7704748B2 (ja) 逐次抗cd19治療
WO2020102728A9 (en) Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
JP2023500338A5 (cg-RX-API-DMAC7.html)
WO2012007576A1 (en) Superior efficacy of cd37 antibodies in cll blood samples
US20250099542A1 (en) Method of treating a tumor with a combination of il-7 protein and vegf antagonist
JP2021525067A5 (cg-RX-API-DMAC7.html)
CN119095869A (zh) 用于预防和/或治疗炎症性病症的靶向共刺激分子的具有嵌合抗原受体的调节性t细胞
US20240139241A1 (en) Compositions and methods for conditioning patients for cell therapy
TW202128755A (zh) 抗原結合蛋白
CN119013309A (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
TW202302642A (zh) 用於治療抗體介導移植物排斥用途之抗cd38抗體
Aldeghaither Identifying Molecular Mechanisms of Resistance to Antibody Dependent Cell Mediated Cytotoxicity (ADCC)
US20230190804A1 (en) Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
CN120302979A (zh) 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
CN118946583A (zh) 用t细胞接合分子治疗前列腺癌的联合治疗方法
TW202611075A (zh) 以雙特異性BCMAxCD3抗體治療輕鏈類澱粉變性症之方法
EA048837B1 (ru) Ступенчатая анти-cd19 терапия
JP2024540320A5 (cg-RX-API-DMAC7.html)
IL256261A (en) Compounds and method for hide1